Molecular diagnostics laboratory P23 Labs reported on Friday the availability of its new P23 Respiratory ONE test to detect respiratory illnesses that share symptoms with COVID-19 when test results for COVID-19 are negative and the patient is still not healthy.
The company added that the P23 Respiratory ONE can detect the common cold, five different Influenza strains and five Coronavirus strains including COVID-19. The test results are available 48 hours from lab receipt.
According to the company, the P23 Respiratory ONE takes a single COVID-19 sample, whether it is the non-invasive saliva sample or the nasal swab sample. The kits are shipped directly to patients to allow sample collection from the comfort of their own home.
If anyone is presenting COVID-19 symptoms and working with their physician to obtain a COVID-19 order, the patient should also tell their physician that they would like to have a test that identifies what illness they do have if it is not COVID-19, concluded the company.
Akeso's ivonescimab meets overall survival endpoint in interim analysis of Phase III HARMONi-2 study
AstraZeneca completes global licence agreement for Zegfrovy
Kazia Therapeutics reports 100% clinical benefit rate in initial paxalisib breast cancer trial
Oxcia receives EMA orphan designation for OXC-201 in idiopathic pulmonary fibrosis
Cizzle Bio presents CIZ1B biomarker blood test for lung cancer at Next Generation Dx Summit
Maverix Medical's Narwhal Cryo System receives FDA 510(k) clearance
Vascarta commences NIH phase I clinical study of VAS-101 in sickle cell disease
AstraZeneca reports positive Phase III results for Tagrisso and Orpathys
HUTCHMED reports positive Phase III results for ORPATHYS and TAGRISSO combination
ArkBio's Ziresovir gains US FDA Phase II clinical trial approval
Pharming launches Joenja in Japan for APDS patients aged four and above
Galvanize Therapeutics' new Aliya EX System completes first commercial procedures